ALNYLAM PHARMACEUTICALS, INC. Quarterly Costs and Expenses in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2017 to Q2 2024.
  • Alnylam Pharmaceuticals, Inc. Costs and Expenses for the quarter ending June 30, 2024 was $611M, a 11.4% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. Costs and Expenses for the twelve months ending June 30, 2024 was $2.24B, a 8.63% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Costs and Expenses for 2023 was $2.11B, a 15.8% increase from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Costs and Expenses for 2022 was $1.82B, a 17.4% increase from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Costs and Expenses for 2021 was $1.55B, a 17.5% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $2.24B $611M +$62.6M +11.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $2.18B $538M +$68.7M +14.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $2.11B $556M +$32.5M +6.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $2.08B $537M +$14.3M +2.74% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $2.06B $549M +$132M +31.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $1.93B $469M +$109M +30.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $1.82B $524M +$70.6M +15.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $1.75B $522M +$153M +41.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $1.6B $417M +$49.8M +13.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $1.55B $360M -$3.83M -1.05% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $1.55B $453M +$95.3M +26.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $1.46B $369M +$18.3M +5.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $1.44B $367M +$63.9M +21.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-28
Q1 2021 $1.38B $364M +$54.2M +17.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q4 2020 $1.32B $358M -$12M -3.24% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-11
Q3 2020 $1.33B $351M +$64.7M +22.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $1.27B $303M +$21.8M +7.77% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $1.25B $310M +$87.6M +39.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 $1.16B $370M +$128M +53.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-11
Q3 2019 $1.03B $286M +$29.7M +11.6% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-11
Q2 2019 $1B $281M +$58.7M +26.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-11
Q1 2019 $942M $222M +$52.8M +31.2% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-11
Q4 2018 $890M $241M +$56.2M +30.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 $833M $257M +$114M +79.6% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 $720M $222M +$85.9M +62.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 $634M $169M +$43.8M +34.9% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 $590M $185M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-14
Q3 2017 $143M Jul 1, 2017 Sep 30, 2017 10-K 2019-02-14
Q2 2017 $136M Apr 1, 2017 Jun 30, 2017 10-K 2019-02-14
Q1 2017 $125M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.